Compare GF & RNAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GF | RNAC |
|---|---|---|
| Founded | 1990 | 2007 |
| Country | Germany | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 184.9M | 217.1M |
| IPO Year | N/A | 2016 |
| Metric | GF | RNAC |
|---|---|---|
| Price | $11.24 | $6.88 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $38.80 |
| AVG Volume (30 Days) | 18.3K | ★ 123.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 0.82% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $38,913,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 49.64 |
| 52 Week Low | $8.80 | $5.98 |
| 52 Week High | $12.82 | $18.80 |
| Indicator | GF | RNAC |
|---|---|---|
| Relative Strength Index (RSI) | 24.91 | 44.41 |
| Support Level | $10.38 | $6.20 |
| Resistance Level | $11.62 | $8.10 |
| Average True Range (ATR) | 0.21 | 0.70 |
| MACD | -0.12 | -0.01 |
| Stochastic Oscillator | 0.00 | 29.27 |
NEW GERMANY FUND INC is a non-diversified, closed-end management investment company. As the investment objective, the fund seeks long-term capital appreciation through investment in middle-market German equities. The fund's portfolio of investment includes investments in different sectors such as the industrials, information technology, material, consumer discretionary, Communication Services, Financials, Consumer Staples, Real Estate, Utilities, Healthcare, Energy, and others. Its portfolio is geographically diversified across the Netherlands, Germany, and Luxembourg.
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. The company leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function.